This invention introduces a novel method to generate stem cell-like memory T (TSCM) cells from CD4+ T cells using MEK1/2 inhibitors. These engineered TSCM cells exhibit enhanced properties including self-renewal, robust antigen-specific responses, and the ability to differentiate into various CD4+ subpopulations. This approach addresses the limitations of current T cell therapies by producing more durable and effective therapeutic cells for treating cancer, infections, and autoimmune disorders.BACKGROUND
T cell therapy is a promising area in immunotherapy, but current methods face challenges such as T cell exhaustion and limited efficacy. This invention provides a solution by re-engineering CD4+ T cells into TSCM cells, offering a more robust and versatile approach to cellular immunotherapy. The technology has potential applications in various diseases, addressing the need for more effective and personalized treatments.
Benefit
Market Application
Intellectual property status
Granted Patent
Patent number : Patent Application No. 18/042,405
Where : USA
Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.
Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Georgetown University
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
